BiotechTube

anidulafungin

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ventilator Associated Pneumonia

Conditions

Ventilator Associated Pneumonia, Respiratory Tract Infection

Trial Timeline

Apr 1, 2010 → Aug 1, 2012

NCT ID
NCT00934934

About anidulafungin

anidulafungin is a phase 2 stage product being developed by Pfizer for Ventilator Associated Pneumonia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00934934. Target conditions include Ventilator Associated Pneumonia, Respiratory Tract Infection.

What happened to similar drugs?

2 of 4 similar drugs in Ventilator Associated Pneumonia were approved

Approved (2) Terminated (2) Active (0)
✅Imipenem + ImipenemMerckApproved
✅Vancomycin + LinezolidPfizerApproved
❌Doripenem + Imipenem-Cilastatin + PlaceboJohnson & JohnsonPhase 3
❌Ceftolozane/Tazobactam + Piperacillin/TazobactamMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT01202253Pre-clinicalCompleted
NCT00934934Phase 2Terminated
NCT01053884Phase 2Terminated
NCT00537329Phase 3Completed
NCT00056381Phase 1/2Completed

Competing Products

9 competing products in Ventilator Associated Pneumonia

See all competitors
ProductCompanyStageHype Score
Doripenem + Imipenem-Cilastatin + PlaceboJohnson & JohnsonPhase 3
32
Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + DoripenemJohnson & JohnsonPhase 2
35
Ceftolozane/Tazobactam + Piperacillin/TazobactamMerckPhase 3
32
Imipenem + ImipenemMerckApproved
43
Vancomycin + LinezolidPfizerApproved
43
LinezolidPfizerPre-clinical
18
aerosolized vancomycin or gentamicinNektar TherapeuticsPhase 2
29
IC43 + PlaceboValneva SEPhase 2
29
CeftobiproleBasilea PharmaceuticaPhase 1
15